Nicotine and Caffeine Co-Use as a Compensatory Response to Early Antipsychotic-Induced Dysfunction: A Case-Based Mechanistic Report

Nicotine and Caffeine Co-Use as a Compensatory Response to Early Antipsychotic-Induced Dysfunction: A Case-Based Mechanistic Report | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Case Report Nicotine and Caffeine Co-Use as a Compensatory Response to Early Antipsychotic-Induced Dysfunction: A Case-Based Mechanistic Report Alexander Dimitriev This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7879544/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Early adverse effects of antipsychotics and SSRIs—such as hyperprolactinemia, affective blunting, cognitive slowing, and akathisia—impair tolerability and adherence. Fast, dose‑limited adjuncts that transiently counter early dopaminergic/cholinergic suppression may bridge the initiation phase without replacing standard care. Case: A young adult on paroxetine 20 mg/day, sulpiride 100 mg/day, and lamotrigine 100 mg/day experienced reproducible improvement in libido, urinary hesitancy, affective responsiveness, and cognitive focus within 30–60 minutes after self‑administered low‑to‑moderate nicotine (≈9 mg/day, pod inhalations) and caffeine (≈200–380 mg/day). Higher cumulative stimulation provoked a short post‑stimulant dysphoric/anxious state, underscoring the need for titration. Mechanistic interpretation: Nicotine (α4β2/α7-nAChR) enhances mesocorticolimbic dopaminergic tone and attentional control, while caffeine (A1/A2A antagonism) disinhibits D2 signaling in the indirect pathway; their convergence can transiently restore fronto-striatal throughput. Clinical implications: Brief, structured co-use under supervision may act as a pragmatic, falsifiable strategy to improve early tolerability, with pharmacovigilance (e.g., monitoring anxiety, sleep, blood pressure and heart rate) and predefined stopping rules. Conclusion: In this case, nicotine–caffeine co-use functioned as a rapid‑onset compensatory approach during early antipsychotic/SSRI therapy. Controlled n‑of‑1 microtrials could test efficacy and safety. clinical pharmacology receptor pharmacology antipsychotics sulpiride hyperprolactinemia nicotine caffeine nAChR (α4β2 α7) Figures Figure 1 Figure 2 Figure 3 Introduction Antipsychotics and SSRIs, especially during initiation, frequently induce dopaminergic and cholinergic suppression, leading to sexual, cognitive, and affective side effects. These iatrogenic effects can manifest within days, impair functioning, and contribute to non-adherence. Current pharmacological strategies to mitigate early dysfunction (e.g., dopamine agonists) act slowly or risk worsening psychiatric symptoms. Thus, there is a need for rapid, accessible compensatory strategies. We outline a Neurochemical Bridge Model: that nicotine and caffeine can transiently compensate for early D2 and 5-HT2-mediated suppression via activation of parallel neuromodulatory systems. This hypothesis is supported by receptor pharmacology and illustrated by a clinical observation. Neurochemical and Pathophysiological Rationale The pathophysiology of early-onset antipsychotic-induced dysfunction involves dopaminergic suppression through D2 receptor antagonism and indirect serotonergic inhibition of cholinergic and dopaminergic tone. Sulpiride, a selective D2 antagonist, blocks mesolimbic and tuberoinfundibular pathways, resulting in decreased dopamine release and hyperprolactinemia. This in turn contributes to blunted affect, reduced libido, and cognitive slowing. Paroxetine, an SSRI, potentiates serotonergic tone that indirectly inhibits dopamine and acetylcholine release via 5-HT2A and 5-HT3 receptor-mediated pathways. The combined pharmacodynamic effect leads to a pronounced hypodopaminergic and hypocholinergic state, manifesting as emotional flattening, urinary hesitancy, and executive dysfunction. Caffeine, as a non-selective adenosine A1/A2A receptor antagonist, reduces tonic adenosinergic inhibition of glutamatergic and dopaminergic neurons. Specifically, in the striatum and prefrontal cortex, A2A blockade enhances dopamine D2 receptor signaling, while also modulating glutamate release. Additionally, caffeine may downregulate AMPA/KA receptor activity and upregulate GABA transporter activity, producing a modulating effect on excitatory/inhibitory balance in frontostriatal circuits [ 9 , 10 , 15 ]. Nicotine, through α4β2 and α7 nicotinic acetylcholine receptor agonism, stimulates acetylcholine release and activates mesocortical and mesolimbic dopamine neurons. Prefrontal α7-nAChR activation is particularly relevant to executive function and cognitive modulation, while stimulation of VTA-projecting circuits facilitates dopaminergic tone. As shown by Wang et al. (2023) [ 16 ], low-dose nicotine (≤ 10 mg/day) enhances prefrontal cognitive function via α7-nAChR-mediated glutamatergic transmission. This mechanistic profile fits the observed clinical response in our case. The combination of caffeine and nicotine may, therefore, create a fast-acting compensatory loop that bypasses suppressed monoaminergic pathways by activating non-overlapping receptor targets. This model predicts improvement in functions most vulnerable to early antipsychotic side effects—libido, cognition, affective responsiveness, and autonomic regulation. The hypothesized interaction network is illustrated in Fig. 1 . Case Presentation A 20-year-old male with anxiety-depressive symptoms began combined pharmacotherapy: paroxetine (20 mg/day), sulpiride (100 mg/day), and lamotrigine (100 mg/day). By day 10, he reported severe libido reduction (1/10), urinary hesitancy, cognitive slowing, and affective flattening. He self-administered: Caffeine: ~200 mg/day (2–3 cups of coffee) Nicotine: ~9 mg/day (nicotine vaporizer) Subjective improvements occurred within 30–60 minutes and remained stable with repeated exposure. In subsequent observation, the caffeine-nicotine combination consistently improved urinary function in the morning, daytime, and early evening, but not reliably after nighttime sulpiride dosing—suggesting a dose-dependent window of effect. Currently, using VAS scales, cognitive function scores improved to ~ 9/10, and fatigue reduced to ~ 3–4/10 compared to baseline. Table 1 summarizes the symptom dynamics associated with stimulant administration. However, higher doses of caffeine and nicotine led to a post-stimulatory syndrome characterized by transient anxiety and dysphoria. This phenomenon has been conceptualized in a recent case-based hypothesis by the same author as a possible neurovascular-psychosomatic syndrome [ 17 ]. The patient provided written informed consent for publication of anonymized clinical details. Table 1 Symptom Dynamics Before and After Stimulant Use Symptom Day 10 (Pre) Day 11 (Post) Change Time to Improvement Libido (0–10 scale) 1 5 Partial recovery ~ 30 min Urinary hesitancy Present Absent Resolved ~ 45 min Affective reactivity Blunted Mildly responsive Improved ~ 30–60 min Cognitive focus Fragmented Improved Mild recovery ~ 45 min Wakefulness Hypoactive Alert Acute improvement ~ 30 min *Legend: Subjective symptoms measured via patient self-assessment.* Discussion This case illustrates the potential of nicotine and caffeine to act as rapid-onset neuromodulators, temporarily reversing the suppressive effects of early antipsychotic and SSRI therapy. Unlike agents such as cabergoline, which require days to normalize prolactin, the nicotine-caffeine combination yielded perceived improvements within an hour. The mechanistic plausibility lies in the stimulation of parallel dopaminergic and cholinergic pathways, bypassing pharmacologically inhibited circuits. While Wang et al. (2023) confirm nicotine's prefrontal effects, our work is the first to demonstrate its synergy with caffeine for autonomic/sexual symptom reversal. These findings align with previous work showing that nAChR activation enhances prefrontal dopamine [ 11 – 14 , 16 ], and that caffeine increases dopaminergic signaling in striatal regions [ 4 , 9 ], modulates glutamate and GABA [ 10 , 15 ], and induces neuroadaptive changes after repeated exposure [ 13 ]. As outlined in Table 2 , conventional dopaminergic agents—such as cabergoline, modafinil, bupropion, and amantadine—are associated with a broad spectrum of adverse effects, including insomnia, anxiety, hallucinations, hypertension, and impulse dysregulation. Notably, several of these agents have been linked to induction of psychotic symptoms, especially in predisposed individuals or at higher doses. Many also carry the risk of pharmacological tolerance or psychological dependence, which can further complicate sustained use. In contrast, the nicotine–caffeine combination exhibits a simpler and more predictable tolerability profile when administered in controlled, low-dose settings, potentially offering a safer neuromodulatory alternative. Accordingly, we compare caffeine and nicotine to other dopaminergic agents in terms of mechanism and onset. Our observations also resonate with Wang et al.’s 2023 review [ 16 ], confirming the fast-acting cognitive benefits of low-dose nicotine in hypodopaminergic conditions. However, Wang et al. did not assess autonomic or sexual functions, and the synergistic effect with caffeine remains unexplored in their analysis. The time- and dose-dependent nature of urinary improvement suggests pharmacodynamic thresholds for stimulant efficacy. The post-stimulatory syndrome observed at higher doses, as recently detailed elsewhere [ 17 ], highlights the importance of clinical supervision and dosing titration in future applications. Figure 3 illustrates the proposed compensatory model of monoaminergic restoration. The observation suggests that low‑to‑moderate nicotine and caffeine can transiently counter early antipsychotic/SSRI-linked dysfunction via convergent receptor mechanisms. Nicotine acting at α4β2/α7-nAChR can enhance mesocorticolimbic dopamine and improve attentional control; caffeine antagonism at A1/A2A may disinhibit D2 signaling within indirect pathways, increase signal‑to‑noise in fronto-striatal circuits, and modulate glutamate/GABA balance. Together, these actions plausibly underwrite the rapid subjective improvements observed. Clinically, any trial of stimulant co-use must be individualized and brief, with explicit pharmacovigilance (monitoring anxiety, sleep, blood pressure and heart rate) and stopping rules for tachycardia, insomnia, or symptom worsening. Importantly, this approach is not a substitution for standard treatment and should be framed as a falsifiable, time‑limited adjunct during the initiation window. Limitations include single‑subject design, reliance on patient‑reported outcomes, and absence of biomarkers (e.g., prolactin, HRV). Future n‑of‑1 cross‑over microtrials (3–7‑day epochs) could test efficacy and safety, incorporating PK/PD covariates (CYP1A2, smoking status) and objective measures (psychomotor tasks). Table 2 Dopamine-Relevant Agents: Comparison of Mechanism, Symptom Targets, Onset, Adaptive Potential, and Side Effects Agent Primary Mechanism Target Symptoms Onset (estimated) Compensatory Potential Major Side Effects Cabergoline D2 receptor agonist Libido, prolactin 3–5 days High Hypotension, behavioral dysregulation, risk of impulse-related dependence Modafinil DA/NE enhancer, orexin activator Fatigue, apathy 4–6 hours Medium Insomnia, anxiety, risk of psychological habituation Bupropion NDRI (DA/NE reuptake inhibitor) Depression, anhedonia 24–48 hours Medium Seizure risk, hypertension, activation-related discomfort Amantadine NMDA antagonist, DA releaser Parkinsonian symptoms, affective blunting 30–60 min Low Hallucinations, cognitive blunting, tolerance potential Nicotine + Caffeine nAChR agonist + adenosine antagonist Cognitive slowing, dysphoria 12–24 hours Dynamic (bidirectional) Mild autonomic activation, transient anxiety, low-dose habituation (manageable in therapeutic context) *Legend: Time to clinical effect and receptor specificity based on published sources. Caffeine/nicotine combination uniquely activates compensatory dopaminergic/cholinergic circuits.* Pharmacokinetic Considerations Although the proposed effect of nicotine and caffeine is primarily mediated by receptor-level modulation of neurotransmission, minor pharmacokinetic interactions cannot be excluded. Caffeine and nicotine may mildly activate hepatic and renal elimination pathways. While paroxetine is metabolized mainly by CYP2D6 and sulpiride is eliminated renally, stimulant-induced sympathetic activation could plausibly accelerate renal clearance of sulpiride. However, this effect is likely minimal and does not interfere with the proposed compensatory mechanism. These possible effects are summarized in Table 3 . Table 3 Possible Pharmacokinetic Interactions Drug Metabolism / Excretion Effect of Nicotine/Caffeine Clinical Relevance Lamotrigine UGT1A4 (hepatic) Unlikely Negligible Nicotine CYP2A6 (hepatic) Autoregulatory Variable Caffeine CYP1A2 (hepatic) ↑ Clearance w/ smoking Known interaction Paroxetine CYP2D6 (hepatic) Minimal, indirect modulation Low Sulpiride Renal excretion ↑ Sympathetic tone → ↑ GFR Possibly mild *Legend: While receptor-level mechanisms remain primary, minor clearance acceleration is hypothetically plausible due to stimulant-induced sympathetic activation.* Limitations This is a single-subject observation without objective biomarker data. Prolactin levels, imaging, and inflammatory markers were not measured. The hypothesis remains speculative until verified in controlled studies. While Wang et al. confirm the cognitive profile of nicotine [ 16 ], the mechanisms underlying improvements in libido and urological function remain to be elucidated. Mechanisms for sexual/urological improvement require dedicated study, as they extend beyond known nicotine/caffeine actions. Conclusion In a young adult initiating antipsychotic/SSRI therapy, co-use of nicotine and caffeine functioned as a rapid‑onset compensatory strategy with perceived gains in cognition, affect, libido, and urinary function. Controlled, short‑term evaluation is warranted. Patient Perspective Understanding the link between stimulants and symptom relief reduced anxiety and improved self‑management. The patient reported confidence in avoiding higher stimulant loads and using pacing strategies during the early treatment phase. Declarations Ethics approval and consent to participate: Not applicable (single anonymized observation without intervention). Consent for publication: Written informed consent was obtained from the patient for publication of anonymized details. Data Availability: The data that support the findings of this study are available from the corresponding author upon reasonable request. Competing interests: The author declares no competing interests. Funding: No specific funding was received for this work. Author contributions: A.D. conceived the observation, collected and interpreted data, drafted and approved the manuscript. AI usage declaration: Language editing assistance only; scientific content and conclusions are the author’s responsibility. Future Directions 1. Randomized trials testing nicotine-caffeine adjuncts in early-phase antipsychotic/SSRI users. 2. Biomarker tracking: prolactin, cytokines, functional neuroimaging. 3. Stratified analysis of patient subtypes most responsive to compensatory stimulation, possibly based on nAChR polymorphisms (e.g., CHRNA7). 4. Quantification of stress and inflammatory biomarkers (IL-6, cortisol) during dose-escalation protocols. Acknowledgements The patient provided informed consent. AI-assisted tools were used for editing. References Weizman A, Maoz B, Treves I, Ben-David M, Gil-Ad I, Laron Z. Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(2):193–8. 10.1016/0278-5846(85)90082-x . Gupta S, Lakshmanan DAM, Khastgir U, Sivakumar T, Varadharajan N, Rajkumar RP. Management of antipsychotic-induced hyperprolactinemia. BJPsych Adv. 2017;23(4):278–86. 10.1192/apt.bp.115.014928 . Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–53. 10.1007/s40263-014-0157-3 . Volkow ND, Wang GJ, Logan J, Alexoff D, Fowler JS, Thanos PK, et al. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Transl Psychiatry. 2015;5(4):e549. 10.1038/tp.2015.46 . Valentine G, Sofuoglu M. Cognitive effects of nicotine: recent progress. Curr Neuropharmacol. 2018;16(4):403–14. 10.2174/1570159X15666171103152136 . Fani K, Changeux JP. Do nicotinic acetylcholine receptors modulate high-order cognitive processing? Trends Neurosci. 2020;43(7):514–26. 10.1016/j.tins.2020.06.001 . López-Arrieta J, Sanz F. Nicotine for Alzheimer's disease. Cochrane Database Syst Rev 2001;Issue 2:CD001749. 10.1002/14651858.CD001749 Nehlig A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacol Rev. 2018;70(2):384–411. 10.1124/pr.117.014407 . Solinas M, Ferré S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci. 2002;22(15):6321–4. 10.1523/JNEUROSCI.22-15-06321.2002 . Vyleta NP, Smith SM. Fast inhibition of glutamate-activated currents by caffeine. PLoS ONE. 2008;3(9):e3155. 10.1371/journal.pone.0003155 . Livingstone PD, Srinivasan J, Kew JN, Dawson LA, Gotti C, Moretti M, Shoaib M, Wonnacott S. α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci. 2009;29(3):539–50. 10.1111/j.1460-9568.2009.06613.x . Sutherland MT, McHugh MJ, Pariyadath V, Stein EA. Neurobiological impact of nicotinic acetylcholine receptor agonists: An activation likelihood estimation meta-analysis of pharmacologic neuroimaging studies. Biol Psychiatry. 2015;78(10):711–20. 10.1016/j.biopsych.2014.12.021 . Weibel J, Lin YS, Landolt HP, Garbazza C, Kolodyazhniy V, Kistler J, et al. Caffeine-dependent changes of sleep-wake regulation: Evidence for adaptation after repeated intake. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109851. 10.1016/j.pnpbp.2019.109851 . de Kloet SF, Mansvelder HD, De Vries TJ. Cholinergic modulation of dopamine pathways through nicotinic acetylcholine receptors. Biochem Pharmacol. 2015;97(4):425–38. 10.1016/j.bcp.2015.07.014 . Kubrusly RCC, da Rosa Valli T, Ferreira MNMR, Souza MH, de Mello FG, Reis HJ, Guimarães FS, de Miranda AS. Caffeine improves GABA transport in the striatum of spontaneously hypertensive rats (SHR). Neurotox Res. 2021;39:1946–58. 10.1007/s12640-021-00423-0 . Wang Q, Du W, Wang H, et al. Nicotine’s effect on cognition, a friend or foe? Prog Neuropsychopharmacol Biol Psychiatry. 2023;124:110723. 10.1016/j.pnpbp.2023.110723 . Dimitriev AA. A Hypothesized Post-Stimulant Neurovascular-Psychosomatic Phenomenon Induced by Caffeine and Nicotine Combination: A Case-Based Report. 2025. 10.5281/zenodo.15562560 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7879544","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Case Report","associatedPublications":[],"authors":[{"id":531094226,"identity":"ddc11c64-598d-4472-be00-12fb64000ffc","order_by":0,"name":"Alexander Dimitriev","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABDklEQVRIiWNgGAWjYDCCwwwMBxgYJKC8Chs7fhCdUEBAywG4ljNpyZINIC0GeLQcgGIwYGw7zLgBzMOjhe84d+Lhj3ss5AzOH3784ceZw8zG51cnfnhgwCDPL3YAqxbJw7wbDhx4JmFscCPNTLKnIp3P7MbbzRJAhxnOnJ2AVYsBWMsBicSZMxjMGHjOWDOb3Ti7AaQlweA2fi31M/uPf/74t42ZcfOMs5t/EKMlgZ8hx0Cat82ZcQN/7za8toD9cuaAhGG/RE6ZtAwwkCVu8G6zSDCQwOkXvvNnN3+oOFAnz8Z/fPPHN6Co7D+7+eaPCht5fmnsWrAACbBKCQKqUAD/AVJUj4JRMApGwQgAAKp0ayert66UAAAAAElFTkSuQmCC","orcid":"","institution":"Independent researcher","correspondingAuthor":true,"prefix":"","firstName":"Alexander","middleName":"","lastName":"Dimitriev","suffix":""}],"badges":[],"createdAt":"2025-10-16 16:08:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7879544/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7879544/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":94775619,"identity":"dbc925fa-2467-42a6-b7de-74ab4cab51e8","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"tiff","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":4718896,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.tiff","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/e71cf64a5d5731ddfc38edd6.tiff"},{"id":94775620,"identity":"51585b67-33b3-406a-a78f-e6ad09cdcf82","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":120773,"visible":true,"origin":"","legend":"","description":"","filename":"DimitrievCaseReportCRPSUBMITFINAL1.docx","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/0dadb262989a2a362dcfd9b9.docx"},{"id":94825441,"identity":"0938416b-4f4c-4f42-963b-5b50890fc923","added_by":"auto","created_at":"2025-10-31 06:50:17","extension":"tiff","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":7545024,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.tiff","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/5f2ea732248d2a9d92616e8e.tiff"},{"id":94824037,"identity":"47074b3e-2a35-488a-972f-c41500e2e0a6","added_by":"auto","created_at":"2025-10-31 06:48:23","extension":"tiff","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":4718896,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.tiff","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/94c628b539593f248d48fb24.tiff"},{"id":94825186,"identity":"df66fdab-46ca-4cad-b214-2794f93f3f7b","added_by":"auto","created_at":"2025-10-31 06:49:57","extension":"json","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":3648,"visible":true,"origin":"","legend":"","description":"","filename":"a4b37fb0ed064d98a92a56d02c0cf7c8.json","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/83f520fe0364c6f45c9f6770.json"},{"id":94775617,"identity":"2a13cfaf-d27f-4fbe-80aa-990aa36dafcd","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"xml","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":57758,"visible":true,"origin":"","legend":"","description":"","filename":"a4b37fb0ed064d98a92a56d02c0cf7c81enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/78cc2fee7398c0fb62821c22.xml"},{"id":94775625,"identity":"8c434331-ad4b-4eaf-b73f-75fee162b518","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"tiff","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":4718896,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.tiff","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/37da92d5492dbfcaa04421b1.tiff"},{"id":94825215,"identity":"290e73fb-53ba-4151-9955-f5ed70ef46c5","added_by":"auto","created_at":"2025-10-31 06:49:58","extension":"tiff","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":7545024,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.tiff","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/da0ef60edec0fdfd95d761c6.tiff"},{"id":94775627,"identity":"d893667d-3aa2-400d-908e-233d97276f83","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"tiff","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":4718896,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.tiff","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/7259718de663da42cc4d9c71.tiff"},{"id":94775621,"identity":"1ca0b609-f0af-4979-8301-3d9e678a125f","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"xml","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":56392,"visible":true,"origin":"","legend":"","description":"","filename":"a4b37fb0ed064d98a92a56d02c0cf7c81structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/b19cdfc0b62807b5fbcbb83b.xml"},{"id":94825370,"identity":"85a44ea2-b5db-470e-815c-e763d7453865","added_by":"auto","created_at":"2025-10-31 06:50:10","extension":"html","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":63496,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/27e6fa5b9ee724fade6a29b7.html"},{"id":94775614,"identity":"aeda3cfc-df90-430a-8883-a018d0a1319d","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":62492,"visible":true,"origin":"","legend":"\u003cp\u003eCase‑Based Mechanistic Report: how nicotine and caffeine bypass antipsychotic-induced dopaminergic and cholinergic suppression.\u003cbr\u003e\nLegend: Parallel activation of α7-nAChR, A1/A2A antagonism, and glutamate/GABA modulation may form a transient compensatory loop restoring frontostriatal signaling.\u003c/p\u003e","description":"","filename":"OnlineFigure1.png","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/c27ae68e3426d651fea5bf93.png"},{"id":94775615,"identity":"10e57f1d-b80c-44c0-b362-4e808443c879","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":45334,"visible":true,"origin":"","legend":"\u003cp\u003eTimeline of subjective symptom dynamics after stimulant intake.\u003cbr\u003e\nLegend: Subject-reported onset and offset of cognitive, autonomic, and affective recovery following self-administered nicotine and caffeine.\u003c/p\u003e","description":"","filename":"OnlineFigure2.png","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/e567195ab5e9767fe90e263b.png"},{"id":94775613,"identity":"5fd269b8-a130-4e4e-af37-fc93de0924d7","added_by":"auto","created_at":"2025-10-30 14:41:22","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":107618,"visible":true,"origin":"","legend":"\u003cp\u003eSchematic of compensatory restoration of monoaminergic signaling during early pharmacotherapy.\u003cbr\u003e\nLegend: Illustration of how nicotine and caffeine may transiently restore dopaminergic/cholinergic signaling during early-phase antipsychotic treatment.\u003c/p\u003e","description":"","filename":"OnlineFigure3.png","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/f3cb1ae51bcedd2f3fddf9d1.png"},{"id":96821614,"identity":"a45a16bd-1525-42e1-9a48-8faa4a27e600","added_by":"auto","created_at":"2025-11-26 12:08:23","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":807794,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7879544/v1/3278ed6f-e2bb-4617-ab65-d7ec6d8bacd5.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Nicotine and Caffeine Co-Use as a Compensatory Response to Early Antipsychotic-Induced Dysfunction: A Case-Based Mechanistic Report","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAntipsychotics and SSRIs, especially during initiation, frequently induce dopaminergic and cholinergic suppression, leading to sexual, cognitive, and affective side effects. These iatrogenic effects can manifest within days, impair functioning, and contribute to non-adherence. Current pharmacological strategies to mitigate early dysfunction (e.g., dopamine agonists) act slowly or risk worsening psychiatric symptoms. Thus, there is a need for rapid, accessible compensatory strategies.\u003c/p\u003e\u003cp\u003eWe outline a Neurochemical Bridge Model: that nicotine and caffeine can transiently compensate for early D2 and 5-HT2-mediated suppression via activation of parallel neuromodulatory systems. This hypothesis is supported by receptor pharmacology and illustrated by a clinical observation.\u003c/p\u003e\n\u003ch3\u003eNeurochemical and Pathophysiological Rationale\u003c/h3\u003e\n\u003cp\u003eThe pathophysiology of early-onset antipsychotic-induced dysfunction involves dopaminergic suppression through D2 receptor antagonism and indirect serotonergic inhibition of cholinergic and dopaminergic tone. Sulpiride, a selective D2 antagonist, blocks mesolimbic and tuberoinfundibular pathways, resulting in decreased dopamine release and hyperprolactinemia. This in turn contributes to blunted affect, reduced libido, and cognitive slowing.\u003c/p\u003e\u003cp\u003eParoxetine, an SSRI, potentiates serotonergic tone that indirectly inhibits dopamine and acetylcholine release via 5-HT2A and 5-HT3 receptor-mediated pathways. The combined pharmacodynamic effect leads to a pronounced hypodopaminergic and hypocholinergic state, manifesting as emotional flattening, urinary hesitancy, and executive dysfunction.\u003c/p\u003e\u003cp\u003eCaffeine, as a non-selective adenosine A1/A2A receptor antagonist, reduces tonic adenosinergic inhibition of glutamatergic and dopaminergic neurons. Specifically, in the striatum and prefrontal cortex, A2A blockade enhances dopamine D2 receptor signaling, while also modulating glutamate release. Additionally, caffeine may downregulate AMPA/KA receptor activity and upregulate GABA transporter activity, producing a modulating effect on excitatory/inhibitory balance in frontostriatal circuits [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eNicotine, through α4β2 and α7 nicotinic acetylcholine receptor agonism, stimulates acetylcholine release and activates mesocortical and mesolimbic dopamine neurons. Prefrontal α7-nAChR activation is particularly relevant to executive function and cognitive modulation, while stimulation of VTA-projecting circuits facilitates dopaminergic tone. As shown by Wang et al. (2023) [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e], low-dose nicotine (≤ 10 mg/day) enhances prefrontal cognitive function via α7-nAChR-mediated glutamatergic transmission. This mechanistic profile fits the observed clinical response in our case.\u003c/p\u003e\u003cp\u003eThe combination of caffeine and nicotine may, therefore, create a fast-acting compensatory loop that bypasses suppressed monoaminergic pathways by activating non-overlapping receptor targets. This model predicts improvement in functions most vulnerable to early antipsychotic side effects—libido, cognition, affective responsiveness, and autonomic regulation. The hypothesized interaction network is illustrated in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e"},{"header":"Case Presentation","content":"\u003cp\u003eA 20-year-old male with anxiety-depressive symptoms began combined pharmacotherapy: paroxetine (20 mg/day), sulpiride (100 mg/day), and lamotrigine (100 mg/day). By day 10, he reported severe libido reduction (1/10), urinary hesitancy, cognitive slowing, and affective flattening.\u003c/p\u003e\u003cp\u003eHe self-administered:\u003c/p\u003e\u003cp\u003eCaffeine: ~200 mg/day (2–3 cups of coffee)\u003c/p\u003e\u003cp\u003eNicotine: ~9 mg/day (nicotine vaporizer)\u003c/p\u003e\u003cp\u003eSubjective improvements occurred within 30–60 minutes and remained stable with repeated exposure. In subsequent observation, the caffeine-nicotine combination consistently improved urinary function in the morning, daytime, and early evening, but not reliably after nighttime sulpiride dosing—suggesting a dose-dependent window of effect. Currently, using VAS scales, cognitive function scores improved to ~ 9/10, and fatigue reduced to ~ 3–4/10 compared to baseline. Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e summarizes the symptom dynamics associated with stimulant administration. However, higher doses of caffeine and nicotine led to a post-stimulatory syndrome characterized by transient anxiety and dysphoria. This phenomenon has been conceptualized in a recent case-based hypothesis by the same author as a possible neurovascular-psychosomatic syndrome [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe patient provided written informed consent for publication of anonymized clinical details.\u003c/p\u003e\u003cdiv class=\"gridtable\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eSymptom Dynamics Before and After Stimulant Use\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"5\"\u003e\u003c/colgroup\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSymptom\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDay 10 (Pre)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDay 11 (Post)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eChange\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eTime to Improvement\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLibido (0–10 scale)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePartial recovery\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e~ 30 min\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eUrinary hesitancy\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePresent\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eAbsent\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eResolved\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e~ 45 min\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAffective reactivity\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eBlunted\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eMildly responsive\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eImproved\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e~ 30–60 min\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCognitive focus\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eFragmented\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eImproved\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eMild recovery\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e~ 45 min\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eWakefulness\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHypoactive\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eAlert\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eAcute improvement\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e~ 30 min\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"5\"\u003e*Legend: Subjective symptoms measured via patient self-assessment.*\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis case illustrates the potential of nicotine and caffeine to act as rapid-onset neuromodulators, temporarily reversing the suppressive effects of early antipsychotic and SSRI therapy. Unlike agents such as cabergoline, which require days to normalize prolactin, the nicotine-caffeine combination yielded perceived improvements within an hour. The mechanistic plausibility lies in the stimulation of parallel dopaminergic and cholinergic pathways, bypassing pharmacologically inhibited circuits. While Wang et al. (2023) confirm nicotine's prefrontal effects, our work is the first to demonstrate its synergy with caffeine for autonomic/sexual symptom reversal.\u003c/p\u003e\u003cp\u003eThese findings align with previous work showing that nAChR activation enhances prefrontal dopamine [\u003cspan additionalcitationids=\"CR12 CR13\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e], and that caffeine increases dopaminergic signaling in striatal regions [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e], modulates glutamate and GABA [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], and induces neuroadaptive changes after repeated exposure [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. As outlined in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e, conventional dopaminergic agents\u0026mdash;such as cabergoline, modafinil, bupropion, and amantadine\u0026mdash;are associated with a broad spectrum of adverse effects, including insomnia, anxiety, hallucinations, hypertension, and impulse dysregulation. Notably, several of these agents have been linked to induction of psychotic symptoms, especially in predisposed individuals or at higher doses. Many also carry the risk of pharmacological tolerance or psychological dependence, which can further complicate sustained use. In contrast, the nicotine\u0026ndash;caffeine combination exhibits a simpler and more predictable tolerability profile when administered in controlled, low-dose settings, potentially offering a safer neuromodulatory alternative. Accordingly, we compare caffeine and nicotine to other dopaminergic agents in terms of mechanism and onset. Our observations also resonate with Wang et al.\u0026rsquo;s 2023 review [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e], confirming the fast-acting cognitive benefits of low-dose nicotine in hypodopaminergic conditions. However, Wang et al. did not assess autonomic or sexual functions, and the synergistic effect with caffeine remains unexplored in their analysis.\u003c/p\u003e\u003cp\u003eThe time- and dose-dependent nature of urinary improvement suggests pharmacodynamic thresholds for stimulant efficacy. The post-stimulatory syndrome observed at higher doses, as recently detailed elsewhere [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e], highlights the importance of clinical supervision and dosing titration in future applications. Figure\u0026nbsp;3 illustrates the proposed compensatory model of monoaminergic restoration.\u003c/p\u003e\u003cp\u003eThe observation suggests that low‑to‑moderate nicotine and caffeine can transiently counter early antipsychotic/SSRI-linked dysfunction via convergent receptor mechanisms. Nicotine acting at α4β2/α7-nAChR can enhance mesocorticolimbic dopamine and improve attentional control; caffeine antagonism at A1/A2A may disinhibit D2 signaling within indirect pathways, increase signal‑to‑noise in fronto-striatal circuits, and modulate glutamate/GABA balance. Together, these actions plausibly underwrite the rapid subjective improvements observed.\u003c/p\u003e\u003cp\u003eClinically, any trial of stimulant co-use must be individualized and brief, with explicit pharmacovigilance (monitoring anxiety, sleep, blood pressure and heart rate) and stopping rules for tachycardia, insomnia, or symptom worsening. Importantly, this approach is not a substitution for standard treatment and should be framed as a falsifiable, time‑limited adjunct during the initiation window.\u003c/p\u003e\u003cp\u003eLimitations include single‑subject design, reliance on patient‑reported outcomes, and absence of biomarkers (e.g., prolactin, HRV). Future n‑of‑1 cross‑over microtrials (3\u0026ndash;7‑day epochs) could test efficacy and safety, incorporating PK/PD covariates (CYP1A2, smoking status) and objective measures (psychomotor tasks).\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eDopamine-Relevant Agents: Comparison of Mechanism, Symptom Targets, Onset, Adaptive Potential, and Side Effects\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"6\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAgent\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePrimary Mechanism\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eTarget Symptoms\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eOnset\u003c/p\u003e\u003cp\u003e(estimated)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eCompensatory Potential\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003eMajor Side Effects\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCabergoline\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eD2 receptor agonist\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eLibido, prolactin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3\u0026ndash;5 days\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eHigh\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eHypotension, behavioral dysregulation, risk of impulse-related dependence\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eModafinil\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDA/NE enhancer, orexin activator\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eFatigue, apathy\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4\u0026ndash;6 hours\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eMedium\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eInsomnia, anxiety, risk of psychological habituation\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eBupropion\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNDRI (DA/NE reuptake inhibitor)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDepression, anhedonia\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e24\u0026ndash;48 hours\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eMedium\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eSeizure risk, hypertension, activation-related discomfort\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAmantadine\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eNMDA antagonist, DA releaser\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eParkinsonian symptoms, affective blunting\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e30\u0026ndash;60 min\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eLow\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eHallucinations, cognitive blunting, tolerance potential\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNicotine\u0026thinsp;+\u0026thinsp;Caffeine\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003enAChR agonist\u0026thinsp;+\u0026thinsp;adenosine antagonist\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eCognitive slowing, dysphoria\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e12\u0026ndash;24 hours\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eDynamic (bidirectional)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eMild autonomic activation, transient anxiety, low-dose habituation (manageable in therapeutic context)\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"6\"\u003e*Legend: Time to clinical effect and receptor specificity based on published sources. Caffeine/nicotine combination uniquely activates compensatory dopaminergic/cholinergic circuits.*\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\n\u003ch3\u003ePharmacokinetic Considerations\u003c/h3\u003e\n\u003cp\u003eAlthough the proposed effect of nicotine and caffeine is primarily mediated by receptor-level modulation of neurotransmission, minor pharmacokinetic interactions cannot be excluded. Caffeine and nicotine may mildly activate hepatic and renal elimination pathways. While paroxetine is metabolized mainly by CYP2D6 and sulpiride is eliminated renally, stimulant-induced sympathetic activation could plausibly accelerate renal clearance of sulpiride. However, this effect is likely minimal and does not interfere with the proposed compensatory mechanism. These possible effects are summarized in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003ePossible Pharmacokinetic Interactions\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDrug\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eMetabolism / Excretion\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eEffect of Nicotine/Caffeine\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eClinical Relevance\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLamotrigine\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eUGT1A4 (hepatic)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eUnlikely\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNegligible\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNicotine\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCYP2A6 (hepatic)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eAutoregulatory\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eVariable\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCaffeine\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCYP1A2 (hepatic)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u0026uarr; Clearance w/ smoking\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eKnown interaction\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eParoxetine\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCYP2D6 (hepatic)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eMinimal, indirect modulation\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eLow\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSulpiride\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRenal excretion\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u0026uarr; Sympathetic tone \u0026rarr; \u0026uarr; GFR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePossibly mild\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"4\"\u003e*Legend: While receptor-level mechanisms remain primary, minor clearance acceleration is hypothetically plausible due to stimulant-induced sympathetic activation.*\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003ch2\u003eLimitations\u003c/h2\u003e\u003cp\u003eThis is a single-subject observation without objective biomarker data. Prolactin levels, imaging, and inflammatory markers were not measured. The hypothesis remains speculative until verified in controlled studies. While Wang et al. confirm the cognitive profile of nicotine [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e], the mechanisms underlying improvements in libido and urological function remain to be elucidated. Mechanisms for sexual/urological improvement require dedicated study, as they extend beyond known nicotine/caffeine actions.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn a young adult initiating antipsychotic/SSRI therapy, co-use of nicotine and caffeine functioned as a rapid‑onset compensatory strategy with perceived gains in cognition, affect, libido, and urinary function. Controlled, short‑term evaluation is warranted.\u003c/p\u003e\n\u003ch3\u003ePatient Perspective\u003c/h3\u003e\n\u003cp\u003eUnderstanding the link between stimulants and symptom relief reduced anxiety and improved self‑management. The patient reported confidence in avoiding higher stimulant loads and using pacing strategies during the early treatment phase.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eEthics approval and consent to participate: Not applicable (single anonymized observation without intervention).\u003c/p\u003e\n\u003cp\u003eConsent for publication: Written informed consent was obtained from the patient for publication of anonymized details.\u003c/p\u003e\n\u003cp\u003eData Availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003eCompeting interests: The author declares no competing interests.\u003c/p\u003e\n\u003cp\u003eFunding: No specific funding was received for this work.\u003c/p\u003e\n\u003cp\u003eAuthor contributions: A.D. conceived the observation, collected and interpreted data, drafted and approved the manuscript.\u003c/p\u003e\n\u003cp\u003eAI usage declaration: Language editing assistance only; scientific content and conclusions are the author\u0026rsquo;s responsibility.\u003c/p\u003e\n\u003ch3\u003eFuture Directions\u003c/h3\u003e\n\u003cp\u003e1. Randomized trials testing nicotine-caffeine adjuncts in early-phase antipsychotic/SSRI users.\u003cbr\u003e\u0026nbsp;2. Biomarker tracking: prolactin, cytokines, functional neuroimaging.\u003cbr\u003e\u0026nbsp;3. Stratified analysis of patient subtypes most responsive to compensatory stimulation, possibly based on nAChR polymorphisms (e.g., CHRNA7).\u003c/p\u003e\n\u003cp\u003e4. Quantification of stress and inflammatory biomarkers (IL-6, cortisol) during dose-escalation protocols.\u003c/p\u003e\n\u003ch3\u003eAcknowledgements\u003c/h3\u003e\n\u003cp\u003eThe patient provided informed consent. AI-assisted tools were used for editing.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eWeizman A, Maoz B, Treves I, Ben-David M, Gil-Ad I, Laron Z. Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(2):193\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/0278-5846(85)90082-x\u003c/span\u003e\u003cspan address=\"10.1016/0278-5846(85)90082-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGupta S, Lakshmanan DAM, Khastgir U, Sivakumar T, Varadharajan N, Rajkumar RP. Management of antipsychotic-induced hyperprolactinemia. BJPsych Adv. 2017;23(4):278\u0026ndash;86. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1192/apt.bp.115.014928\u003c/span\u003e\u003cspan address=\"10.1192/apt.bp.115.014928\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePeuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421\u0026ndash;53. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s40263-014-0157-3\u003c/span\u003e\u003cspan address=\"10.1007/s40263-014-0157-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVolkow ND, Wang GJ, Logan J, Alexoff D, Fowler JS, Thanos PK, et al. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Transl Psychiatry. 2015;5(4):e549. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/tp.2015.46\u003c/span\u003e\u003cspan address=\"10.1038/tp.2015.46\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eValentine G, Sofuoglu M. Cognitive effects of nicotine: recent progress. Curr Neuropharmacol. 2018;16(4):403\u0026ndash;14. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2174/1570159X15666171103152136\u003c/span\u003e\u003cspan address=\"10.2174/1570159X15666171103152136\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFani K, Changeux JP. Do nicotinic acetylcholine receptors modulate high-order cognitive processing? Trends Neurosci. 2020;43(7):514\u0026ndash;26. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.tins.2020.06.001\u003c/span\u003e\u003cspan address=\"10.1016/j.tins.2020.06.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eL\u0026oacute;pez-Arrieta J, Sanz F. Nicotine for Alzheimer's disease. Cochrane Database Syst Rev 2001;Issue 2:CD001749. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/14651858.CD001749\u003c/span\u003e\u003cspan address=\"10.1002/14651858.CD001749\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNehlig A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacol Rev. 2018;70(2):384\u0026ndash;411. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1124/pr.117.014407\u003c/span\u003e\u003cspan address=\"10.1124/pr.117.014407\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSolinas M, Ferr\u0026eacute; S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci. 2002;22(15):6321\u0026ndash;4. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1523/JNEUROSCI.22-15-06321.2002\u003c/span\u003e\u003cspan address=\"10.1523/JNEUROSCI.22-15-06321.2002\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVyleta NP, Smith SM. Fast inhibition of glutamate-activated currents by caffeine. PLoS ONE. 2008;3(9):e3155. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1371/journal.pone.0003155\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0003155\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLivingstone PD, Srinivasan J, Kew JN, Dawson LA, Gotti C, Moretti M, Shoaib M, Wonnacott S. α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci. 2009;29(3):539\u0026ndash;50. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1460-9568.2009.06613.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1460-9568.2009.06613.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSutherland MT, McHugh MJ, Pariyadath V, Stein EA. Neurobiological impact of nicotinic acetylcholine receptor agonists: An activation likelihood estimation meta-analysis of pharmacologic neuroimaging studies. Biol Psychiatry. 2015;78(10):711\u0026ndash;20. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.biopsych.2014.12.021\u003c/span\u003e\u003cspan address=\"10.1016/j.biopsych.2014.12.021\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWeibel J, Lin YS, Landolt HP, Garbazza C, Kolodyazhniy V, Kistler J, et al. Caffeine-dependent changes of sleep-wake regulation: Evidence for adaptation after repeated intake. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109851. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.pnpbp.2019.109851\u003c/span\u003e\u003cspan address=\"10.1016/j.pnpbp.2019.109851\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ede Kloet SF, Mansvelder HD, De Vries TJ. Cholinergic modulation of dopamine pathways through nicotinic acetylcholine receptors. Biochem Pharmacol. 2015;97(4):425\u0026ndash;38. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bcp.2015.07.014\u003c/span\u003e\u003cspan address=\"10.1016/j.bcp.2015.07.014\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKubrusly RCC, da Rosa Valli T, Ferreira MNMR, Souza MH, de Mello FG, Reis HJ, Guimar\u0026atilde;es FS, de Miranda AS. Caffeine improves GABA transport in the striatum of spontaneously hypertensive rats (SHR). Neurotox Res. 2021;39:1946\u0026ndash;58. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s12640-021-00423-0\u003c/span\u003e\u003cspan address=\"10.1007/s12640-021-00423-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWang Q, Du W, Wang H, et al. Nicotine\u0026rsquo;s effect on cognition, a friend or foe? Prog Neuropsychopharmacol Biol Psychiatry. 2023;124:110723. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.pnpbp.2023.110723\u003c/span\u003e\u003cspan address=\"10.1016/j.pnpbp.2023.110723\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDimitriev AA. A Hypothesized Post-Stimulant Neurovascular-Psychosomatic Phenomenon Induced by Caffeine and Nicotine Combination: A Case-Based Report. 2025. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.5281/zenodo.15562560\u003c/span\u003e\u003cspan address=\"10.5281/zenodo.15562560\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"clinical pharmacology, receptor pharmacology, antipsychotics, sulpiride, hyperprolactinemia, nicotine, caffeine, nAChR (α4β2, α7)","lastPublishedDoi":"10.21203/rs.3.rs-7879544/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7879544/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eBackground: Early adverse effects of antipsychotics and SSRIs—such as hyperprolactinemia, affective blunting, cognitive slowing, and akathisia—impair tolerability and adherence. Fast, dose‑limited adjuncts that transiently counter early dopaminergic/cholinergic suppression may bridge the initiation phase without replacing standard care.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCase: A young adult on paroxetine 20 mg/day, sulpiride 100 mg/day, and lamotrigine 100 mg/day experienced reproducible improvement in libido, urinary hesitancy, affective responsiveness, and cognitive focus within 30–60 minutes after self‑administered low‑to‑moderate nicotine (≈9 mg/day, pod inhalations) and caffeine (≈200–380 mg/day). Higher cumulative stimulation provoked a short post‑stimulant dysphoric/anxious state, underscoring the need for titration. Mechanistic interpretation: Nicotine (α4β2/α7-nAChR) enhances mesocorticolimbic dopaminergic tone and attentional control, while caffeine (A1/A2A antagonism) disinhibits D2 signaling in the indirect pathway; their convergence can transiently restore fronto-striatal throughput. Clinical implications: Brief, structured co-use under supervision may act as a pragmatic, falsifiable strategy to improve early tolerability, with pharmacovigilance (e.g., monitoring anxiety, sleep, blood pressure and heart rate) and predefined stopping rules.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eConclusion: In this case, nicotine–caffeine co-use functioned as a rapid‑onset compensatory approach during early antipsychotic/SSRI therapy. Controlled n‑of‑1 microtrials could test efficacy and safety.\u003c/p\u003e","manuscriptTitle":"Nicotine and Caffeine Co-Use as a Compensatory Response to Early Antipsychotic-Induced Dysfunction: A Case-Based Mechanistic Report","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-30 14:41:17","doi":"10.21203/rs.3.rs-7879544/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"6d36400a-f554-46cb-856e-8e78001595e4","owner":[],"postedDate":"October 30th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-11-26T12:08:13+00:00","versionOfRecord":[],"versionCreatedAt":"2025-10-30 14:41:17","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7879544","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7879544","identity":"rs-7879544","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}